{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:43:32Z","timestamp":1761587012308,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.intimp.2021.108324","type":"journal-article","created":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T06:54:58Z","timestamp":1635576898000},"page":"108324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"PB","title":["Methotrexate as a safe immunosuppressive agent during the COVID-19 pandemic"],"prefix":"10.1016","volume":"101","author":[{"given":"Zakiye","family":"Ganjei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoorvash","family":"Faraji Dana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sepehr","family":"Ebrahimi-Dehkordi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fereshte","family":"Alidoust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1053-778X","authenticated-orcid":false,"given":"Kiumars","family":"Bahmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2021.108324_b0005","unstructured":"W.H. Organization, WHO Director-General\u2019s remarks at the media briefing on 2019-nCoV on 11 February 2020, 2020."},{"issue":"5","key":"10.1016\/j.intimp.2021.108324_b0010","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41577-020-0308-3","article-title":"COVID-19: immunopathology and its implications for therapy","volume":"20","author":"Cao","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2021.108324_b0015","article-title":"Transmission of SARS-CoV-2: a review of viral, host, and environmental factors","author":"Meyerowitz","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.intimp.2021.108324_b0020","article-title":"The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong?","volume":"104799","author":"Darif","year":"2021","journal-title":"Microb. Pathog."},{"issue":"2","key":"10.1016\/j.intimp.2021.108324_b0025","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/nri3152","article-title":"Expanding roles for CD4+ T cells in immunity to viruses","volume":"12","author":"Swain","year":"2012","journal-title":"Nat. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2021.108324_b0030","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13511","article-title":"A.S.o.T.I.D.C.o. Practice, RNA respiratory viral infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Manuel","year":"2019","journal-title":"Clin. Transplant."},{"issue":"3","key":"10.1016\/j.intimp.2021.108324_b0035","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40257-020-00514-2","article-title":"Managing cutaneous immune-mediated diseases during the COVID-19 pandemic","volume":"21","author":"Torres","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.intimp.2021.108324_b0040","doi-asserted-by":"crossref","unstructured":"M. Hordinsky, M. Ericson, Autoimmunity: alopecia areata, Journal of Investigative Dermatology Symposium Proceedings, Elsevier, 2004, pp. 73\u201378.","DOI":"10.1111\/j.1087-0024.2004.00835.x"},{"issue":"1","key":"10.1016\/j.intimp.2021.108324_b0045","first-page":"267","article-title":"Oral Pulse Betamethasone, Methotrexate, and Combination Therapy to Treat Severe Alopecia Areata: A Randomized, Double-blind, Placebo-controlled, Clinical Trial","volume":"20","author":"Asilian","year":"2021","journal-title":"Iranian J. Pharm. Res."},{"issue":"4","key":"10.1016\/j.intimp.2021.108324_b0050","first-page":"187","article-title":"Teratogen update: methotrexate, Birth Defects Research Part A: Clinical and Molecular","volume":"94","author":"Hyoun","year":"2012","journal-title":"Teratology"},{"issue":"2\u20133","key":"10.1016\/j.intimp.2021.108324_b0055","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0014-4827(69)90039-1","article-title":"Studies on in vitro lymphocyte proliferation in cultures synchronized by the inhibition of DNA synthesis: I. Variability of S plus G2 periods of first generation cells","volume":"56","author":"Steffen","year":"1969","journal-title":"Exp. Cell Res."},{"issue":"3","key":"10.1016\/j.intimp.2021.108324_b0060","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrrheum.2010.5","article-title":"Methotrexate\u2014how does it really work?","volume":"6","author":"Chan","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2021.108324_b0065","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","article-title":"Methotrexate and its mechanisms of action in inflammatory arthritis","volume":"16","author":"Cronstein","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"issue":"20","key":"10.1016\/j.intimp.2021.108324_b0070","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.3390\/ijms20205023","article-title":"Methotrexate an old drug with new tricks","volume":"20","author":"Bedoui","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2021.108324_b0075","series-title":"2020 International Conference on Public Health and Data Science (ICPHDS), IEEE","first-page":"333","article-title":"Risk factors and indicators for COVID-19 severity: Clinical severe cases and their implications to prevention and treatment","author":"Tang","year":"2020"},{"key":"10.1016\/j.intimp.2021.108324_b0080","doi-asserted-by":"crossref","DOI":"10.26633\/RPSP.2020.72","article-title":"Ferritin levels and COVID-19","volume":"44","author":"Vargas-Vargas","year":"2020","journal-title":"Revista Panamericana de Salud P\u00fablica"},{"issue":"7","key":"10.1016\/j.intimp.2021.108324_b0085","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/ajt.15869","article-title":"Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression","volume":"20","author":"Zhu","year":"2020","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.intimp.2021.108324_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2021.01.022","article-title":"COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients","author":"Belsky","year":"2021","journal-title":"J. Infect."},{"issue":"25","key":"10.1016\/j.intimp.2021.108324_b0095","first-page":"2881","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients Blood","volume":"136","author":"Vijenthira","year":"2020","journal-title":"J. Am. Soc. Hematol."},{"issue":"1","key":"10.1016\/j.intimp.2021.108324_b0100","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.bbmt.2010.11.008","article-title":"Viral infections in immunocompromised patients","volume":"17","author":"Englund","year":"2011","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"1","key":"10.1016\/j.intimp.2021.108324_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41421-020-00231-4","article-title":"Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility","volume":"6","author":"Wang","year":"2020","journal-title":"Cell Discovery"},{"key":"10.1016\/j.intimp.2021.108324_b0110","doi-asserted-by":"crossref","unstructured":"F.R.S.S.S.C.I. consortium, contributors, Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients, Ann. Rheum. Dis. 80(4) (2021) 527\u2013538.","DOI":"10.1136\/annrheumdis-2020-218310"},{"key":"10.1016\/j.intimp.2021.108324_b0115","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1007\/s10067-020-05190-5","article-title":"Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment","volume":"39","author":"Soy","year":"2020","journal-title":"Clin. Rheumatol."},{"issue":"2","key":"10.1016\/j.intimp.2021.108324_b0120","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clim.2004.09.001","article-title":"The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules","volume":"114","author":"Johnston","year":"2005","journal-title":"Clin. Immunol."},{"issue":"23","key":"10.1016\/j.intimp.2021.108324_b0125","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.intimp.2021.108324_b0130","doi-asserted-by":"crossref","first-page":"599","DOI":"10.12816\/0037811","article-title":"The effect of mehotrexate in the treatment of alopecia areata","volume":"67","author":"Alsufyani","year":"2017","journal-title":"Egyptian J. Hospital Med."},{"key":"10.1016\/j.intimp.2021.108324_b0135","doi-asserted-by":"crossref","unstructured":"J.L. Mu\u00f1oz-Carrillo, J.F. Contreras-Cordero, O. Guti\u00e9rrez-Coronado, P.T. Villalobos-Guti\u00e9rrez, L.G. Ramos-Gracia, V.E. Hern\u00e1ndez-Reyes, Cytokine profiling plays a crucial role in activating immune system to clear infectious pathogens, Immune response activation and immunomodulation, IntechOpen2018.","DOI":"10.5772\/intechopen.80843"},{"issue":"9366","key":"10.1016\/j.intimp.2021.108324_b0140","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0140-6736(03)13077-2","article-title":"Coronavirus as a possible cause of severe acute respiratory syndrome","volume":"361","author":"Peiris","year":"2003","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.intimp.2021.108324_b0145","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1749-6632.1998.tb11153.x","article-title":"Activation and Methotrexate-Mediated Suppression of the TNF\u03b1 Promoter in T Cells and Macrophages","volume":"859","author":"Becker","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2021.108324_b0150","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.4049\/jimmunol.167.5.2911","article-title":"Methotrexate suppresses NF-\u03baB activation through inhibition of I\u03baB\u03b1 phosphorylation and degradation","volume":"167","author":"Majumdar","year":"2001","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2021.108324_b0155","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","article-title":"Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer","volume":"18","author":"Jones","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2021.108324_b0160","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harbor Perspect. Biol."},{"issue":"3","key":"10.1016\/j.intimp.2021.108324_b0165","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s00296-002-0267-y","article-title":"Methotrexate inhibits interleukin-6 production in patients with juvenile rheumatoid arthritis","volume":"23","author":"Aggarwal","year":"2003","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.intimp.2021.108324_b0170","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","article-title":"Immunological and inflammatory functions of the interleukin-1 family","volume":"27","author":"Dinarello","year":"2009","journal-title":"Annu. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2021.108324_b0175","first-page":"2092","article-title":"Low dose methotrexate decreases intraarticular prostaglandin and interleukin 1 levels in antigen induced arthritis in rabbits","volume":"23","author":"Novaes","year":"1996","journal-title":"J. Rheumatol."},{"issue":"8","key":"10.1016\/j.intimp.2021.108324_b0180","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1007\/s00296-011-1867-1","article-title":"Methotrexate attenuates the Th17\/IL-17 levels in peripheral blood mononuclear cells from healthy individuals and RA patients","volume":"32","author":"Li","year":"2012","journal-title":"Rheumatol. Int."},{"issue":"3","key":"10.1016\/j.intimp.2021.108324_b0185","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/jmv.26512","article-title":"Methotrexate inhibits SARS-CoV-2 virus replication \u201cin vitro\u201d","volume":"93","author":"Caruso","year":"2021","journal-title":"J. Med. Virol."},{"issue":"3","key":"10.1016\/j.intimp.2021.108324_b0190","first-page":"387","article-title":"The risk of hospitalized infection in patients with rheumatoid arthritis","volume":"35","author":"Smitten","year":"2008","journal-title":"J. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2021.108324_b0195","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/jcm8010015","article-title":"Risk of infection with methotrexate therapy in inflammatory diseases: a systematic review and meta-analysis","volume":"8","author":"Ibrahim","year":"2019","journal-title":"J. Clin. Med."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921009607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921009607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:36:53Z","timestamp":1761586613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921009607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":39,"alternative-id":["S1567576921009607"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108324","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Methotrexate as a safe immunosuppressive agent during the COVID-19 pandemic","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108324","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108324"}}